Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure

Circulation

Volumn 112, Issue 24, 2005, Pages 3745-3753

  Angus, Derek C ^a   Linde Zwirble, Walter T ^b   Tam, S William ^c   Ghali, Jalal K ^d   Sabolinski, Michael L ^c   Villagra, Victor G ^e   Winkelmayer, Wolfgang C ^f   Worcel, Manuel ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b ZD Associates   (United States)

^c NitroMed Inc   (United States)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e Health and Technology Vector Inc   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiovascular diseases; Cost benefit analysis; Heart failure; Nitric oxide; Vasodilation

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; ISOSORBIDE DINITRATE; SPIRONOLACTONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COMBINATION; DRUG COST; FEMALE; FIXED DOSE COMBINATION; FOLLOW UP; HEALTH CARE COST; HEART FAILURE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGRO; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESOURCE ALLOCATION; SOCIETY; TREATMENT OUTCOME; UNITED STATES; VASODILATATION; CONGESTIVE HEART FAILURE; ECONOMICS; ETHNOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY;

AFRICAN CONTINENTAL ANCESTRY GROUP; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; HYDRALAZINE; ISOSORBIDE DINITRATE; LENGTH OF STAY; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 33644876602     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.563882     Document Type: Article

References (24)

1. American Heart Association. Heart Disease and Stroke Statistics: 2005 Update. Available at: http://www.americanheart.org/downloadable/heart/ 11050481905292005Statcharts.ppt. Last update: January 2005. Accessed May 18, 2005.
2. Yancy CW. Does race matter in heart failure? Am Heart J. 2003;146:203-206.
3. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340:609-616.
4. Tanus-Santos JE, Desai M, Flockhart DA. Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics. 2001;11:719-725.
5. Kalinowski L, Dobrucki IT, Malinski T. Race-specific differences in endothelial function: predisposition of African Americans to vascular diseases. Circulation. 2004;109:2511-2517.
6. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-2057.
7. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. JAMA. 1996;276:1339-1341.
8. 2003 Medicare Hospital Discharge Database. Washington, DC: DHHS; 2004.
9. US Department of Labor, Bureau of Labor Statistics. Consumer Price Indexes. Available at: http://www.bls.gov/cpi/home.htm. Last update: May 2005. Accessed: May 20, 2005.
10. Whittle J, Lin CJ, Lave JR, Fine MJ, Delaney KM, Joyce DZ, Young WW, Kapoor WN. Relationship of provider characteristics to outcomes, process, and costs of care for community-acquired pneumonia. Med Care. 1998;36:977-987.
11. Ellis SG, Miller DP, Brown KJ, Omoigui N, Howell GL, Kutner M, Topol EJ. In-hospital cost of percutaneous coronary revascularization: critical determinants and implications. Circulation. 1995;92:741-747.
12. Medicare Utilization for Part B (Supplementary Medical Insurance SMI). Baltimore, Md: Centers for Medicare and Medicaid Services; 2004.
13. 2004 Drug Topics Red Book. Montvale, NJ: Thompson Medical Economics; 2004.
14. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237.
15. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, for the Panel on Cost-Effectiveness in Health and Medicine. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1253-1258.
16. Cheng RCH. Bootstrap methods in computer simulation experiments. In: Lilegdon WR, Goldsman D, Goldsman C, Alexopoulos C, Kang K, eds. Proceedings of the 1995 Winter Conference on Simulation (WSC '95, Arlington, VA, Dec. 3-6). New York, NY: ACM Press; 1995.
17. Efron B. Bootstrap methods: another look at the jackknife. Ann Stat. 1979;7:1-26.
18. Fieller EC. Some problems in interval estimation. J Royal Stat Soc Series B (Methodological). 1954;16:175-183.
19. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials: Vasodilator-Heart Failure Trial Study Group. J Card Fail. 1999;5:178-187.
20. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 2001;344:1351-1357.
21. Bloche MG. Race-based therapeutics. N Engl J Med. 2004;351:2035-2037.
22. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care. 2000;9:2-6.
23. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, Schwartz JS. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147-1152.
24. Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2004;148:122-128.